Jardiance vs Tresiba: Long-Term Durability of Blood Sugar Response

How Each Drug Sustains Glycemic Control Over Time

Empagliflozin drives glucose out through the kidney regardless of pancreatic function, so its effect does not depend on intact beta-cell reserve. Insulin degludec replaces the basal insulin that a failing pancreas can no longer provide. These two mechanisms produce durability profiles that look very different on a multi-year treatment curve.

Empagliflozin Durability: The Insulin-Independent Advantage

The glycosuric mechanism of SGLT2 inhibition does not require functioning beta cells, which is why empagliflozin's A1C-lowering effect can persist even as type 2 diabetes progresses. In the pooled four-year extension of the EMPA-REG OUTCOME program, empagliflozin 10 mg and 25 mg maintained A1C reductions that tracked closely with the 52-week results, with no signal of waning efficacy attributable to the drug itself [1].

A secondary analysis of EMPA-REG OUTCOME (N=7,020 patients with established cardiovascular disease) confirmed that empagliflozin 10 mg or 25 mg reduced the risk of cardiovascular death by 38% vs. Placebo (hazard ratio 0.62, 95% CI 0.49 to 0.77, P<0.001) [1]. That trial ran 3.1 median years, making it one of the longer double-blind empagliflozin datasets available.

What does erode over time with SGLT2 inhibitors is the eGFR-dependent component: once eGFR falls below approximately 30 mL/min/1.73 m², the glucose-lowering effect of empagliflozin diminishes because there is less filtered glucose to block reabsorption. The 2023 ADA Standards of Care note this threshold and recommend reassessment of glycemic strategy when eGFR drops to that level [2].

Insulin Degludec Durability: Titration as the Mechanism

Tresiba's durability story is different in a fundamental way. The drug does not lose potency as diabetes progresses. The limiting factor is not the molecule but the clinician's willingness to titrate the dose upward. In the BEGIN ONCE LONG trial (N=1,030, 52 weeks), insulin degludec produced an A1C reduction of 1.06% from a baseline of 8.2%, non-inferior to insulin glargine U-100, with 25% lower rates of confirmed nocturnal hypoglycemia [3].

Because basal insulin therapy can always be dose-escalated, it has no pharmacological ceiling on glycemic efficacy. The practical ceiling is hypoglycemia risk and patient-reported injection burden. Degludec's ultra-flat pharmacokinetic profile (half-life approximately 25 hours, duration of action approximately 42 hours) is designed to reduce both the day-to-day glucose variability and the risk of nocturnal hypoglycemia that can limit aggressive titration [4].

What Happens When Both Mechanisms Are Combined

Many patients with type 2 diabetes eventually use both an SGLT2 inhibitor and a basal insulin. The 2023 ADA/EASD consensus report on managing hyperglycemia explicitly supports adding an SGLT2 inhibitor to basal insulin when A1C remains above target, citing additive glucose lowering, weight benefit, and CV protection [2]. In a 52-week open-label trial, adding empagliflozin 10 mg to existing basal insulin therapy reduced A1C by an additional 0.5% and body weight by 2.5 kg vs. Placebo, with no increase in severe hypoglycemia [5].

EMPA-REG OUTCOME vs. DEVOTE: Reading the Durability Trials Side by Side

These are the two most important long-term outcome trials for each drug. Comparing them directly requires understanding what each trial was designed to measure and how their populations differed.

EMPA-REG OUTCOME Design and Glycemic Findings

EMPA-REG OUTCOME enrolled 7,020 adults with type 2 diabetes and established atherosclerotic cardiovascular disease across 42 countries. Median follow-up was 3.1 years. The primary endpoint was a three-point MACE composite. Empagliflozin met that endpoint (HR 0.86, P<0.001 for non-inferiority; HR 0.86, P=0.04 for superiority) [1].

On the glycemic side, mean A1C at baseline was 8.07%. Empagliflozin 10 mg reduced A1C by approximately 0.54% at week 12, with that reduction maintained through week 164 in the extension, a finding that provides 3+ years of durability data for the oral agent [1].

DEVOTE Design and Hypoglycemia Findings

DEVOTE enrolled 7,637 adults with type 2 diabetes at high cardiovascular risk. Participants were randomized to insulin degludec or insulin glargine U-100, both titrated to a fasting glucose target of 71 to 90 mg/dL. The trial ran 2 years median. Degludec was non-inferior to glargine for the MACE primary endpoint (HR 0.91, 95% CI 0.78 to 1.06, P<0.001 for non-inferiority) [6].

The key durability signal in DEVOTE was hypoglycemia. Severe hypoglycemia occurred in 4.9% of degludec patients vs. 6.6% of glargine patients (rate ratio 0.60, 95% CI 0.48 to 0.76, P<0.001) [6]. Lower hypoglycemia rates matter for long-term glycemic sustainability: patients who experience recurrent severe hypoglycemia reduce their own doses or stop injecting, directly undermining glycemic durability regardless of what the drug itself can do.

A1C Durability at 2 Years: Numbers from Both Trials

• EMPA-REG OUTCOME: A1C from 8.07% baseline, reduced by approximately 0.54%, maintained at 164 weeks [1].
• DEVOTE: A1C from 8.4% baseline (degludec arm), reduced to 7.5% at 2 years (approximately 0.9% reduction) with a mean final dose of 65 U/day [6].

The raw A1C reduction is larger for degludec in these trial populations, largely because basal insulin was added on top of existing therapy in patients who had already failed oral agents, and because insulin titration can achieve any target given adequate dose escalation. These are not equivalent populations or equivalent treatment stages.

Cardiovascular and Renal Durability: The Outcomes That Matter Most

For a drug comparison framed around "durability," A1C alone is an incomplete lens. Patients and clinicians care whether the treatment reduces the risk of heart failure hospitalization, kidney function decline, and all-cause mortality over a decade of use.

Empagliflozin's Cardiorenal Signal

EMPA-REG OUTCOME showed a 35% reduction in hospitalization for heart failure (HR 0.65, 95% CI 0.50 to 0.85) and a 39% reduction in incident or worsening nephropathy (HR 0.61, 95% CI 0.53 to 0.70) [1]. These benefits emerged within months and persisted through the 3.1-year median follow-up, suggesting they are not attributable to glycemic lowering alone. Hemodynamic and natriuretic mechanisms are likely involved.

The subsequent EMPEROR-Reduced trial (N=3,730, published 2020) confirmed empagliflozin's heart failure benefit in patients with HFrEF regardless of diabetes status [7]. That finding broadens the durability argument: empagliflozin's cardiorenal benefits are partially decoupled from its glucose-lowering function.

Insulin Degludec's Cardiovascular Profile

DEVOTE established cardiovascular safety for degludec, an important regulatory milestone, but did not demonstrate superiority for MACE. The drug does not carry an independent cardiorenal benefit signal comparable to that of SGLT2 inhibitors. Basal insulin remains essential for glycemic control, not for direct organ protection.

One consideration that does affect long-term cardiovascular durability is hypoglycemia. DEVOTE's MACE rate correlated with severe hypoglycemia history (adjusted HR for MACE after severe hypoglycemia: 3.49 in a post-hoc analysis) [6]. By reducing severe hypoglycemia rates by 40% vs. Glargine, degludec may indirectly support better cardiovascular outcomes during long-term titrated therapy.

Real-World Durability: What Happens Off-Protocol

Randomized controlled trials enroll motivated patients with structured follow-up. Real-world durability is often worse.

SGLT2 Persistence Data

A 2021 retrospective cohort study of 18,373 U.S. Patients initiating SGLT2 inhibitors found 12-month medication persistence of approximately 57%, and 24-month persistence of approximately 44% [8]. The primary reason for discontinuation was not adverse effects but cost and insurance coverage gaps. Among patients who remained on therapy, A1C reductions were consistent with trial data.

Insulin Persistence and Titration Gaps

Real-world data on basal insulin persistence show a different pattern. A large pharmacy claims analysis found that fewer than 30% of patients initiating basal insulin achieved A1C <7% within 12 months, largely because titration was inadequate rather than because the drug failed pharmacologically [9]. Clinical inertia, the tendency to underdose insulin to avoid hypoglycemia or weight gain, is the most commonly cited mechanism.

Degludec's lower hypoglycemia burden may reduce this inertia. In the SWITCH 2 trial (N=721 crossover study, insulin-treated T2D), patients titrated to the same fasting glucose target on degludec vs. Glargine U-100 achieved modestly better A1C at 32 weeks (mean difference 0.12%) with 30% fewer nocturnal hypoglycemia episodes [10].

Head-to-Head Comparison Table

| Feature | Empagliflozin (Jardiance) | Insulin Degludec (Tresiba) | |---|---|---| | Route | Oral, once daily | Subcutaneous injection, once daily | | Mechanism | SGLT2 inhibition, glucosuria | Basal insulin replacement | | A1C reduction (monotherapy) | 0.5 to 0.8% | 1.0 to 1.5% (titration-dependent) | | Durability ceiling | eGFR-dependent <30 mL/min | None pharmacologically; limited by titration | | Weight effect | 2 to 3 kg loss | 1 to 3 kg gain | | Hypoglycemia risk (alone) | Very low | Low vs. Glargine; moderate overall | | CV death reduction | 38% in EMPA-REG OUTCOME [1] | Non-inferior to glargine in DEVOTE [6] | | HF hospitalization | 35% reduction [1] | No significant benefit | | Renal protection | Yes (nephropathy reduction 39%) [1] | Not demonstrated | | Long-term trial data | 3.1 years (EMPA-REG OUTCOME) | 2 years (DEVOTE) | | Cost (approximate US) | $600, $700/month without coverage | $350, $500/month without coverage |

Who Should Be on Which Drug: A Decision Framework

The choice between empagliflozin and insulin degludec is rarely binary. Most patients with type 2 diabetes who require one of these agents eventually need both. The clinical question is usually sequencing, not selection.

Start with Empagliflozin When:

• A1C is 7.0 to 9.0% and the patient retains meaningful beta-cell function (C-peptide positive, not severely insulin-deficient).
• The patient has established atherosclerotic cardiovascular disease, heart failure with reduced ejection fraction, or CKD with eGFR 20 to 60 mL/min/1.73 m², all indications supported by the 2023 ADA Standards [2].
• Weight loss is a treatment goal.
• Injectable therapy is not acceptable to the patient at this stage.
• eGFR is above 30 mL/min/1.73 m².

Add or Transition to Insulin Degludec When:

• A1C remains above 9.0 to 10.0% despite oral combination therapy, indicating significant insulin deficiency.
• Fasting glucose is consistently above 180 mg/dL despite maximal oral therapy.
• The patient is symptomatic (polyuria, polydipsia, weight loss) and requires rapid glucose correction.
• Pregnancy is planned or confirmed (empagliflozin is not approved in pregnancy).
• Type 1 diabetes is confirmed or strongly suspected (LADA presentation).

When Both Are Appropriate Together

The ADA 2023 consensus statement notes: "For patients with type 2 diabetes on basal insulin who have not achieved glycemic targets, adding an SGLT2 inhibitor is recommended based on evidence of A1C reduction and cardiovascular benefit" [2]. At that stage, the patient would be on both degludec (for basal coverage) and empagliflozin (for glycosuric lowering and organ protection), and the durability question shifts to whether adequate titration is occurring.

Safety Profile and Long-Term Tolerability

Durability of any therapy depends partly on whether patients can tolerate it for years without significant adverse effects.

Empagliflozin Long-Term Safety

The most clinically significant long-term risk with empagliflozin is diabetic ketoacidosis (DKA), which occurs rarely (approximately 0.1 to 0.2 per 100 patient-years) but can occur even at near-normal blood glucose levels [11]. Genital mycotic infections are common (approximately 5 to 10% of women, 3% of men) but rarely cause discontinuation. Fournier's gangrene is a rare but serious FDA-labeled risk [12].

Over the 3.1 years of EMPA-REG OUTCOME, no new safety signals emerged beyond those seen at 24 weeks, suggesting the long-term safety profile is consistent [1].

Insulin Degludec Long-Term Safety

The primary long-term safety concern with any insulin is hypoglycemia and weight gain. DEVOTE's 2-year dataset showed a mean weight gain of 1.9 kg in the degludec arm, which is lower than some earlier basal insulins but still directionally opposite to empagliflozin [6]. Injection site reactions are uncommon with modern pen delivery systems. Insulin antibody formation to degludec is similar to other basal analogs and has not been shown to reduce clinical efficacy over time [4].

Lipodystrophy at injection sites can accumulate over years and impairs insulin absorption, a real-world durability concern that clinical trials do not fully capture. Rotating injection sites and periodic site assessment are standard clinical guidance [13].

Switching Between Jardiance and Tresiba: Clinical Considerations

Switching from empagliflozin to insulin degludec is common as type 2 diabetes progresses. The reverse, switching from insulin degludec to empagliflozin, is uncommon but relevant in specific clinical scenarios.

Switching Jardiance to Tresiba

Patients on empagliflozin who progress to significant insulin deficiency (rising A1C despite empagliflozin plus metformin, persistent hyperglycemia above 250 to 300 mg/dL, or symptomatic hyperglycemia) typically require basal insulin. In this transition, empagliflozin is not necessarily discontinued. Continuing empagliflozin while starting degludec at a low initial dose (10 U/day, titrating by 2 U every 3 days per standard degludec titration algorithms) is a well-supported approach [2].

If empagliflozin is stopped at the time of insulin initiation, expect A1C to rise by approximately 0.5 to 0.8% from the loss of the SGLT2 effect, requiring more aggressive insulin titration to compensate.

Switching Tresiba to Jardiance

This transition is less common but may be appropriate if: (1) a patient who was started on insulin urgently is later confirmed to have preserved beta-cell function, (2) the patient achieves significant A1C improvement and the insulin dose can be weaned, or (3) the patient's cardiorenal risk profile changes and SGLT2 inhibitor benefits become the priority.

Insulin should be tapered, not abruptly stopped. A standard approach is reducing the degludec dose by 20 to 30% when empagliflozin is initiated, then titrating down over 4 to 8 weeks with fasting glucose monitoring. Abrupt insulin cessation in a patient with significant beta-cell failure will cause rapid glucose deterioration.

Practical Monitoring Over the Long Term

Monitoring Empagliflozin Durability

• Check A1C every 3 months until stable, then every 6 months.
• Monitor eGFR at least annually. If eGFR falls below 30 mL/min/1.73 m², the glucose-lowering effect will diminish; discuss whether continuing for renal/CV protection alone is appropriate.
• Screen for genital symptoms at each visit during the first year.
• Hold empagliflozin 3 to 5 days before elective surgery or prolonged fasting to reduce euglycemic DKA risk [12].

Monitoring Insulin Degludec Durability

• Fasting blood glucose is the primary titration metric. Target 71 to 90 mg/dL per DEVOTE protocol [6].
• Assess injection technique and site rotation at every visit. Poor technique is among the most correctable causes of apparent insulin failure.
• Review dose logs. A patient on 80+ units of degludec with A1C above 8.5% likely needs prandial insulin or an SGLT2 inhibitor added, not a higher basal dose.
• Weight gain above 5 kg from baseline warrants reassessment of the full regimen.